PRISM Study-Pruritus Relief Through Itch Scratch Modulation (PRISM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03497975|
Recruitment Status : Active, not recruiting
First Posted : April 13, 2018
Last Update Posted : February 2, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Prurigo Nodularis||Drug: Nalbuphine ER Tablets Other: Matching Placebo Tablets||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||360 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||Randomized, double-blinded, placebo-controlled, 2-arm study with an open label extension period following double-blind treatment.|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Matching Placebo|
|Official Title:||A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)|
|Actual Study Start Date :||August 7, 2018|
|Actual Primary Completion Date :||May 10, 2022|
|Estimated Study Completion Date :||February 28, 2023|
Active Comparator: Active
162 mg nalbuphine ER tablets, BID
Drug: Nalbuphine ER Tablets
Active Nalbuphine ER Tablets
Other Name: NAL ER Tablets
Placebo Comparator: Placebo
Matching placebo tablets
Other: Matching Placebo Tablets
Matching Tablets with no active substance
- Comparison of percentage of responders by arm [ Time Frame: 14 weeks ]To evaluate the effect of NAL ER on itch as assessed by the percentage of Responders ('response' is defined as a ≥ 4-point reduction in the 7-day average Worst Itch - Numerical Rating Scale [WI-NRS])
- Change from baseline for itch-related quality of life: ItchyQoL total score [ Time Frame: 14 weeks ]To evaluate the effect of NAL ER on itch-related quality of life as assessed by the ItchyQoL total score
- Change from baseline for Prurigo Nodularis skin lesions [ Time Frame: 14 weeks ]To evaluate the effect of NAL ER on Prurigo Nodularis (PN) skin lesions as assessed by the Prurigo Activity Score (PAS) Question 5a
- Change from baseline for sleep disturbance [ Time Frame: at week 14 ]To evaluate the effect of NAL ER on sleep as assessed by the PROMIS Sleep Disturbance Short Form 8a
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Individuals diagnosed with generalized nodular PN, covering 2 separate body parts, and 10 or more pruriginous nodules
- Severe itch due to PN
- Age 18 years and older at the time of consent, and a life expectancy of at least 18 months.
- Individuals using antidepressants must be on a stable dose for a minimum of 4 weeks prior to screening.
- Pruritus due to localized PN (only one body part affected), or less than 10 nodules
- Active, uncontrolled, pruritic dermatoses in need of treatment (such as atopic dermatitis or bullous pemphigoid for example).
- Unresolved acute secondary dermatoses active (unresolved) in the last (a) 4 weeks: localized contact dermatitis, environmental exposures, superficial burns, or viral exanthems; (b) 8 weeks: skin or environmental infestations, such as scabies, lice, or bed bugs.
- Other non-dermatologic diseases that could be a potential cause of concomitant pruritus (e.g., thyroid disease, celiac disease, hepatitis C virus [HCV]) must either have resolved, been successfully treated (i.e., HCV RNA negative) or must be successfully managed with stable, optimized treatment (e.g., thyroid replacement, dietary management with resolution of symptoms, respectively) for at least 3 months prior to screening
- History of a major psychiatric disorder such as bipolar disorder or schizophrenia. History of active substance abuse in the last 3 years.
- Known intolerance (GI, CNS symptoms) or hypersensitivity/drug allergy to opioids.
Use of certain concomitant medications and treatments within a period prior to the study, or requirement for these medications during the study:
- Potential subjects taking opiates, gabapentin, pregabalin, calcineurin inhibitors, cannabinoid agonists, capsaicin, cryosurgery, topical doxepin, thalidomide or methotrexate, topical antihistamines or topical corticosteroids require a 14-day washout.
- Within 4 weeks prior to screening: ultraviolet (UV)-therapy, exposure to any investigational medication, including placebo
- Within 3 months prior to screening: Non-insulin biologics (including monoclonal antibodies) that modify the immune system,
- Individuals taking monoamine oxidase inhibitors are excluded, as concomitant opiate use may increase the risk for serotonin syndrome.
- Myocardial infarction or acute coronary syndrome within the previous 3 months, as reported by the subject.
- Individuals with prolonged QTcF
Individuals with HIV can be included if they meet the following criteria: (a) currently on a stable (> 6 months stable use) and well tolerated highly active antiretroviral therapy regimen; (b) CD4 count > 500 cells/mL; and (c) HIV ribonucleic acid (RNA) < 50 copies/mL documented for at least 6 months prior to enrollment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03497975
|Study Director:||David Clark, MD||Trevi Therapeutics|
|Responsible Party:||Trevi Therapeutics|
|Other Study ID Numbers:||
|First Posted:||April 13, 2018 Key Record Dates|
|Last Update Posted:||February 2, 2023|
|Last Verified:||January 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents